All News MannKind Corporation

Equities

MNKD

US56400P7069

Real-time Estimate Cboe BZX Other stock markets 03:35:20 2024-04-30 pm EDT			5-day change	1st Jan Change
4.155 ^USD	-2.46%		-0.24%	+14.01%

12:05pm	MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases	CI
Apr. 29	MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases	06:05am	AQ
MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases	06:05am	CI
MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment	Apr. 29	MT
MannKind Gets FDA Clearance for Clofazimine IND Application	Apr. 29	DJ
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease	Apr. 29	AQ
MannKind Corporation Announces IND Clearance from U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial Lung Disease	Apr. 29	CI
MannKind Repays Certain Debt Obligations	Apr. 03	AQ
MannKind CFO Binder to Retire in April, Names New CFO	Mar. 26	MT
MannKind Announces CFO Transition	Mar. 26	AQ
MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024	Mar. 26	CI
MannKind Corporation Appoints Steven B. Binder as Executive Vice President, Special Projects	Mar. 26	CI
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps	Mar. 11	AQ
MannKind Corporation Announces INHALE-3 Study?s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections and Insulin Pumps	Mar. 11	CI
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8	Mar. 05	AQ
MannKind Corporation Announces Participation at Upcoming Conferences	Mar. 04	AQ
Transcript : MannKind Corporation, Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Earnings Flash (MNKD) MANNKIND Reports Q4 Revenue $58.5M, vs. Street Est of $53.1M	Feb. 27	MT
MannKind Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update	Feb. 27	AQ
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024	Feb. 20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News MannKind Corporation

Equities

MNKD

US56400P7069

All News

Filters